triazolam (Halcion)
Jump to navigation
Jump to search
Introduction
Tradename: Halcion. DEA-controlled substance: class 4.
Indications
insomnia, difficulty initiating sleep
Dosage
Tabs: 0.125 & 0.25 mg.
Pharmacokinetics
- ultra short-acting benzodiazepine
- metabolized in liver by cyt P450 3A4
- primarily metabolized by hydroxylation
- principal metabolite is alpha-hydroxytriazolam
- metabolites are pharmacologically inactive[2]
elimination via kidney
1/2life = 2-3 hours
protein binding = 88-92 %
Adverse effects
- profound anterograde amnesia
- early morning rebound & anxiety[6]
- drug adverse effects of benzodiazepines
- drug adverse effects of psychotropic agents
- drug adverse effects of sedatives
Drug interactions
- any drug that inhibits cyt P450 3A4 may increase levels of triazolam
- any drug that induces cyt P450 3A4 may diminish levels of triazolam
- drug interaction(s) of methadone in combination with benzodiazepines
- drug interaction(s) of benzodiazepines with antidepressants
- drug interaction(s) of benzodiazepines with thiazide diuretics
- drug interaction(s) of antipsycotics with benzodiazepines
- drug interaction(s) of antidepressants with benzodiazepines
- drug interaction(s) of beta-adrenergic receptor antagonists with benzodiazepines
- drug interaction(s) of beta-adrenergic receptor antagonists (except atenolol) with benzodiazepines
- drug interaction(s) of alcoholic beverage with benzodiazepines
- drug interaction(s) of benzodiazepine with opiates
Laboratory
More general terms
Additional terms
Component of
References
- ↑ Jump up to: 1.0 1.1 The Pharmacological Basis of Therapeutics, 9th ed. Gilman et al, eds. Permagon Press/McGraw Hill, 1996.
- ↑ Jump up to: 2.0 2.1 2.2 Manual of Medical Therapeutics, 28th ed, Ewald & McKenzie (eds), Little, Brown & Co, Boston, 1995, pg 7
- ↑ Saunders Manual of Medical Practice, Rakel (ed), WB Saunders, Philadelphia, 1996, pg 1087-89
- ↑ Clinical Guide to Laboratory Tests, NW Tietz (ed) 3rd ed, WB Saunders, Philadelpha 1995
- ↑ Prescriber's Letter 13(3): 2006 Cytochrome P450 drug interactions Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=220233&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ Jump up to: 6.0 6.1 Geriatrics Review Syllabus, American Geriatrics Society, 5th edition, 2002-2004